Lit­tle Aldeyra's shares rock­et high­er as its first PhI­II eye drug tri­al scores, clear­ing path to NDA

Aldeyra Ther­a­peu­tics’ first for­ay in­to Phase III is a suc­cess, the eye drug de­vel­op­er said, set­ting it up for a po­ten­tial NDA fil­ing by the end of the year.

The top-line re­sults in al­ler­gic con­junc­tivi­tis fol­low a sim­i­lar­ly up­beat an­nounce­ment last Sep­tem­ber that re­prox­alap made the cut in a Phase IIb for dry eye dis­ease — a con­nec­tion that Aldeyra made sure to high­light.

“Giv­en that ap­prox­i­mate­ly half of al­ler­gic con­junc­tivi­tis pa­tients al­so suf­fer from oc­u­lar dry­ness, we be­lieve the AL­LE­VI­ATE re­sults high­light the rel­e­vance of re­prox­alap to our cur­rent Phase 3 pro­gram in dry eye dis­ease,” pres­i­dent and CEO Todd Brady said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER